The Next Beat: Kerendia (Finerenone) for your patients with HF with LVEF >= 40%

This presentation follows Lily and Armand, two hypothetical patients with heart failure with preserved
ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) who are at
elevated risk for cardiovascular (CV) death, and heart failure (HF) events leading to hospitalizations. The
program aims to educate cardiologists and explore the role of KERENDIA, a selective, non-steroidal
mineralocorticoid receptor antagonist, in reducing the risk of CV death, hospitalization for heart failure,
and urgent HF visits in patients with HF and a left ventricular ejection fraction (LVEF) ≥40%.